ArticleJournal of virology2009
Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step.
Article in Journal of virology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 103 citations in OpenAlex.
- Molecular Basis of the Divergent Immunogenicity of Two Pediatric Tick-Borne Encephalitis Virus Vaccines.Journal of virology · 2016Trial
- A distinct E dimer epitope underlies selective recognition by a protective human West Nile virus antibody.EMBO reports · 2026Article
- Article
- A single residue in domain II of envelope protein of yellow fever virus is critical for neutralization sensitivity.Journal of virology · 2025Article
- Antibody-mediated control mechanisms of viral infections.Immunological reviews · 2024Review
- Review
- Single B cell transcriptomics identifies multiple isotypes of broadly neutralizing antibodies against flaviviruses.PLoS pathogens · 2023Article
- Development of Antibody-Based Therapeutics Against West Nile Virus in Plants.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Engineering the Single Domain Antibodies Targeting Receptor Binding Motifs Within the Domain III of West Nile Virus Envelope Glycoprotein.Frontiers in microbiology · 2022Article
- Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries.Cell discovery · 2021Article
- Mechanism of differential Zika and dengue virus neutralization by a public antibody lineage targeting the DIII lateral ridge.The Journal of experimental medicine · 2020Article
- Broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics.eLife · 2019Article
- Crystal structure of Usutu virus envelope protein in the pre-fusion state.Virology journal · 2018Article
- Article
- Viral-Induced Enhanced Disease Illness.Frontiers in microbiology · 2018Review
- Development of Antibody Therapeutics against Flaviviruses.International journal of molecular sciences · 2017Review
- Transplantation of a quaternary structure neutralizing antibody epitope from dengue virus serotype 3 into serotype 4.Scientific reports · 2017Article
- Bispecific antibodies for viral immunotherapy.Human vaccines & immunotherapeutics · 2017Review
- Vaccination strategies against Zika virus.Current opinion in virology · 2017Review
- A single mutation in the envelope protein modulates flavivirus antigenicity, stability, and pathogenesis.PLoS pathogens · 2017Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 3 countries.
Funding
Abstract
West Nile virus (WNV) is a neurotropic flavivirus that is now a primary cause of epidemic encephalitis in North America. Studies of mice have demonstrated that the humoral immune response against WNV limits primary infection and protects against a secondary challenge. The most-potent neutralizing mouse monoclonal antibodies (MAbs) recognize an epitope on the lateral ridge of domain III (DIII-lr) of the envelope (E) protein. However, studies with serum from human patients show that antibodies against the DIII-lr epitope comprise, at best, a minor component of the human anti-WNV antibody response. Herein, we characterize in detail two WNV-specific human MAbs, CR4348 and CR4354, that were isolated from B-cell populations of convalescent patients. These MAbs strongly neutralize WNV infection of cultured cells, protect mice against lethal infection in vivo, and yet poorly recognize recombinant forms of the E protein. Instead, CR4348 and CR4354 bind determinants on intact WNV virions and subviral particles in a pH-sensitive manner, and neutralization is altered by mutations at the dimer interface in domain II and the hinge between domains I and II, respectively. CR4348 and CR4354 human MAbs neutralize infection at a postattachment step in the viral life cycle, likely by inhibiting acid-induced fusion within the endosome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.